使用和不使用储雾罐装置的非专利色甘酸钠吸入器的相对肺部生物利用度。

Relative lung bioavailability of generic sodium cromoglycate inhalers used with and without a spacer device.

作者信息

Aswania O, Chrystyn H

机构信息

Pharmacy Practice, School of Pharmacy, Bradford, BD7 1DP, UK.

出版信息

Pulm Pharmacol Ther. 2001;14(2):129-33. doi: 10.1006/pupt.2001.0279.

DOI:10.1006/pupt.2001.0279

PMID:11273794

Abstract

The relative lung bioavailability of sodium cromoglycate following inhalation has been evaluated using urinary drug excretion in nine healthly volunteers. Each inhaled four 5 mg sodium cromoglycate doses from a generic metered dose inhaler (MDI) and when it was attached to large volume spacer (MDI + VOL). A breath-actuated MDI was also evaluated either used on its own (EB) or attached to a small volume spacer tube (EBO). The mean (SD) urinary excretion of sodium cromoglycate in the first 30 min post-inhalation was 34.1 (20.2), 211.7 (123.5), 29.3 (19.5) and 52.8 (36.0) microg following MDI, MDI+VOL, EB and EBO, respectively. The cumulative mean (SD) urinary excretion of sodium cromoglycate over the 24 h post-inhalation was 364.7 (266.2), 1227.1 (459.0), 280.2 (155.4) and 429.5 (176.7) microg. A metered dose inhaler attached to a large volume spacer delivers more sodium cromoglycate to the lungs than any other inhalation method.

摘要

已通过测量9名健康志愿者的尿药排泄量，评估了吸入色甘酸钠后的相对肺生物利用度。每位志愿者分别使用普通定量吸入器（MDI）吸入4剂5毫克色甘酸钠，以及将其连接到大容量储雾罐（MDI + VOL）后吸入。还评估了单独使用的呼吸驱动定量吸入器（EB）或连接到小容量储雾管（EBO）后的情况。吸入后前30分钟，MDI、MDI + VOL、EB和EBO吸入后色甘酸钠的平均（标准差）尿排泄量分别为34.1（20.2）、211.7（123.5）、29.3（19.5）和52.8（36.0）微克。吸入后24小时内色甘酸钠的累积平均（标准差）尿排泄量分别为364.7（266,2）、1227.1（459.0）、280.2（155.4）和429.5（176.7）微克。连接到大容量储雾罐的定量吸入器比其他任何吸入方法向肺部输送的色甘酸钠都更多。